Skip to main content
. 2015 Oct 7;10(10):e0140120. doi: 10.1371/journal.pone.0140120

Fig 1. SDS-PAGE of the purified anti-CD20 IgG1 rituximab variants.

Fig 1

The purified fucosylated (A) and nonfucosylated (B) anti-CD20 IgG1 variants were subjected to nonreducing and reducing 5–20% SDS-PAGE analyses. Lane M: molecular mass marker, lane 1: Y296G, lane 2: Y296E, lane 3: Y296L, lane 4: Y296F, lane 5: Y296D, lane 6: Y296P, lane 7: Y296H, lane 8: Y296W, lane 9: Y296S, lane 10: Y296R, lane 11: Y296N, lane12: Y296V, lane 13: Y296 A, lane 14: Y296I, lane 15: Y296C, lane 16: Y296T, lane 17: Y296K, lane 18: Y296M, and lane 19: Y296Q.